Zobrazeno 1 - 10
of 729
pro vyhledávání: '"Wee-Joo Chng"'
Autor:
Sinan Xiong, Jianbiao Zhou, Tze King Tan, Tae-Hoon Chung, Tuan Zea Tan, Sabrina Hui-Min Toh, Nicole Xin Ning Tang, Yunlu Jia, Yi Xiang See, Melissa Jane Fullwood, Takaomi Sanda, Wee-Joo Chng
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-21 (2024)
Abstract Multiple myeloma is a hematological malignancy arising from immunoglobulin-secreting plasma cells. It remains poorly understood how chromatin rewiring of regulatory elements contributes to tumorigenesis and therapy resistance in myeloma. Her
Externí odkaz:
https://doaj.org/article/a72d588788c3426aa48efeac9ff0d625
Autor:
Wee-Joo Chng, Chandramouli Nagarajan, Shang-Yi Huang, Pankaj Malhotra, Yu-Yan Hwang, Vivian Blunk, Manmohan Singh, Lin Wang
Publikováno v:
Heliyon, Vol 10, Iss 21, Pp e39698- (2024)
Multiple myeloma (MM) accounts for almost 15 % of all neoplastic malignancies around the globe. This systematic review intends to analyse data on the treatment and management of MM in selected regions in Asia to identify and prioritize areas that nee
Externí odkaz:
https://doaj.org/article/f234975d478044bc8c3dd95cf441fbb4
Autor:
Jianbiao Zhou, Wee-Joo Chng
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Acute myeloid leukemia (AML) is a complex and heterogeneous group of aggressive hematopoietic stem cell disease. The presence of diverse and functionally distinct populations of leukemia cells within the same patient’s bone marrow or blood poses a
Externí odkaz:
https://doaj.org/article/4195a1ce02d74646bf74c4d7f0641781
Autor:
Boheng Li, Qidi Zhou, Qin Wan, Xuan Qiao, Shangying Chen, Jianbiao Zhou, Zhijun Wuxiao, Lei Luo, Siok-Bian Ng, Jieping Li, Wee-Joo Chng
Publikováno v:
Clinical Epigenetics, Vol 15, Iss 1, Pp 1-16 (2023)
Abstract Background Overexpressed EZH2 is oncogenically involved in the pathogenesis of different cancerous contexts including extranodal natural killer/T cell lymphoma (ENKTL). However, the underlying mechanisms of EZH2 upregulation have not been fu
Externí odkaz:
https://doaj.org/article/8a31cc0ef54a4c1c9a923fd4f0e59efc
Autor:
Wee-Lee Chan, Vanessa Cui Lian Chong, Ian Jun Yan Wee, Li Mei Poon, Esther Hian Lee Chan, Joanne Lee, Yen-Lin Chee, Anand D. Jeyasekharan, Wee-Joo Chng, Miny Samuel, Sanjay de Mel
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-11 (2023)
Abstract Rituximab-based chemo-immunotherapy is currently the standard first-line treatment for Waldenstrom macroglobulinaemia (WM), while ibrutinib has emerged as an alternative. In the absence of randomised trials (RCTs) comparing these regimens, t
Externí odkaz:
https://doaj.org/article/ff40f63f9b554a7eb8b5c591b218190b
Autor:
Phyllis S.Y. Chong, Jing Yuan Chooi, Sze Lynn Julia Lim, Tae-Hoon Chung, Reinhard Brunmeir, Aaron Chung Yong Leow, Sabrina Hui Min Toh, Kalpnaa Balan, Muhamad Irfan Bin Azaman, Zhengwei Wu, Nagavidya Subramaniam, Leah A Vardy, Wee-Joo Chng
Publikováno v:
Haematologica, Vol 109, Iss 6 (2023)
REIIBP is a lysine methyltransferase aberrantly expressed through alternative promoter usage of NSD2 locus in t(4;14)-translocated multiple myeloma (MM). Clinically, t(4;14) translocation is an adverse prognostic factor found in approximately 15% of
Externí odkaz:
https://doaj.org/article/f19e38c9080845be90a8baff6bb37aa2
Autor:
Jianbiao Zhou, Sabrina Hui-Min Toh, Tze King Tan, Kalpnaa Balan, Jing Quan Lim, Tuan Zea Tan, Sinan Xiong, Yunlu Jia, Siok-Bian Ng, Yanfen Peng, Anand D. Jeyasekharan, Shuangyi Fan, Soon Thye Lim, Chin-Ann Johnny Ong, Choon Kiat Ong, Takaomi Sanda, Wee-Joo Chng
Publikováno v:
Molecular Cancer, Vol 22, Iss 1, Pp 1-20 (2023)
Abstract Background Extranodal natural killer/T-cell lymphoma (NKTL) is an aggressive type of non-Hodgkin lymphoma with dismal outcome. A better understanding of disease biology and key oncogenic process is necessary for the development of targeted t
Externí odkaz:
https://doaj.org/article/846e95d9de9a442a8d6a7330386245b8
Autor:
Wee-Joo Chng, Sagar Lonial, Gareth J. Morgan, Shinsuke Iida, Philippe Moreau, Shaji K. Kumar, Philip Twumasi-Ankrah, Miguel Villarreal, Ajeeta B. Dash, Alexander Vorog, Xiaoquan Zhang, Kaveri Suryanarayan, Richard Labotka, Meletios A. Dimopoulos, S. Vincent Rajkumar
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract Some cytogenetic abnormalities (CAs) are associated with poorer prognosis in multiple myeloma (MM); proteasome inhibitors appear to benefit patients with high-risk CAs. We evaluated 2247 MM patients from the TOURMALINE-MM1/-MM2/-MM3/-MM4 tri
Externí odkaz:
https://doaj.org/article/ee0fc4f557c4467dbd0a08848e6a28b8
Autor:
Andrew Spencer, Olga Samoilova, Wee‐Joo Chng, Richard Labotka, Cong Li, Kwang‐Wei Wu, Nakul Saxena, Xu Yan, Jae Hoon Lee, Meral Beksac
Publikováno v:
eJHaem, Vol 3, Iss 4, Pp 1241-1251 (2022)
Abstract Ixazomib‐lenalidomide‐dexamethasone (ixazomib‐Rd) showed clinical efficacy over placebo‐Rd in patients with relapsed/refractory multiple myeloma (MM) in the TOURMALINE‐MM1 trial. Over a median follow‐up of ∼85 months, as patien
Externí odkaz:
https://doaj.org/article/ac5e08cef8eb4d8db5c4c2f0bd81a0d0
Autor:
Chieh Yang Koo, Huili Zheng, Li Ling Tan, Ling-Li Foo, Raymond Seet, Jun-Hua Chong, Derek J. Hausenloy, Wee-Joo Chng, A. Mark Richards, Chi-Hang Lee, Mark Y. Chan
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Abstract Patients with cancer are at increased risk of myocardial infarction (MI) and stroke. Guidelines do not address lipid profile targets for these patients. Within the lipid profiles, we hypothesized that patients with cancer develop MI or strok
Externí odkaz:
https://doaj.org/article/8b38c1176a004a2d9f1d6989ff41e272